Coagulation Factor IX (human, recombinant)

Coagulation Factor IX is a vitamin K-dependent plasma serine protease involved in the intrinsic and extrinsic pathways of the blood coagulation cascade.^1,2 It is composed of an N-terminal domain containing carboxylated glutamic acid residues (Gla domain), two EGF-like domains, a linker module, and a C-terminal trypsin-like catalytic peptidase domain.³ Coagulation Factor IX is produced as an inactive precursor, which is activated to Factor IXaβ following signal peptide cleavage, glycosylation, and further cleavage by Factor XIa or VIIa.³ In its activated form, Factor IXaβ, in complex with Factor VIIIa, converts Factor X to Factor Xa, the activated form.⁴ Mutations in F9, the gene encoding Factor IX, are responsible for the X-linked bleeding disorder hemophilia B, characterized by mild to severe deficits in blood coagulation.¹ Cayman’s Coagulation Factor IX (human, recombinant) protein can be used for enzyme activity applications. This protein consists of 444 amino acids, has a calculated molecular weight of 50 kDa, and a predicted N-terminus of Thr29 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 60-80 kDa due to glycosylation.

WARNING This product is not for human or veterinary use.

1. Tjärnlund-Wolf, A., and Lassila, R. Phenotypic characterization of haemophilia B - Understanding the underlying biology of coagulation factor IX. Haemophilia 25(4), 56-574 (2019).

2. Vermeer, C. Vitamin K: The effect on health beyond coagulation - An overview. Food Nutr. Res. 56(1), (2012).

3. Brandstetter, H., Bauer, M., Huber, R., et al. X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. USA 92(21), 9796-9800 (1995).

4. Schenone, M., Furie, B.C., and Furie, B. The blood coagulation cascade. Curr. Opin. Hematol. 11(4), 272-277 (2004).